Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

Genentech releases Phase III PRIMA study findings

Genentech releases Phase III PRIMA study findings

FDA approves Supplemental New Drug Application for DOXIL

FDA approves Supplemental New Drug Application for DOXIL

Gene variation associated with resistance to chemotherapy drug in women with breast cancer

Gene variation associated with resistance to chemotherapy drug in women with breast cancer

New research sheds light on ways to improve treatment for aggressive breast cancer

New research sheds light on ways to improve treatment for aggressive breast cancer

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Chemo improves survival among older breast cancer patients

Chemo improves survival among older breast cancer patients

Gene alterations associated with response to anthracycline therapy for breast cancer

Gene alterations associated with response to anthracycline therapy for breast cancer

Study looks at shikonin for human gastric adenocarcinoma

Study looks at shikonin for human gastric adenocarcinoma

Mycophenolate mofetil may be an alternative therapy for lupus nephritis

Mycophenolate mofetil may be an alternative therapy for lupus nephritis

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Rituximab useful for advanced indolent lymphoma

Rituximab useful for advanced indolent lymphoma

Rituximab reduces kidney inflammation in patients with severe lupus nephritis

Rituximab reduces kidney inflammation in patients with severe lupus nephritis

Tau protein expression predicts breast cancer survival in an unexpected way

Tau protein expression predicts breast cancer survival in an unexpected way

Trial looks at new treatment for solid cancer tumors and non-Hodgkin's lymphoma

Trial looks at new treatment for solid cancer tumors and non-Hodgkin's lymphoma

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Novel leukemia therapy shows promise for high-risk patients

Novel leukemia therapy shows promise for high-risk patients

Adding Taxotere to chemotherapy regimen improves survival in early breast cancer

Adding Taxotere to chemotherapy regimen improves survival in early breast cancer

Injections of N-acetyl cysteine may help 'chemobrain'

Injections of N-acetyl cysteine may help 'chemobrain'

"HiCy" drug regimen reverses multiple sclerosis symptoms in selected patients

"HiCy" drug regimen reverses multiple sclerosis symptoms in selected patients